RecruitingNCT07375225
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy - The ALINET Registry
Sponsor
Federico II University
Enrollment
1,500 participants
Start Date
Dec 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria1
- \- Patients under alirocumab 300mg treatment.
Exclusion Criteria2
- Age < 18 years o > 80 years;
- Patients who refuse to participate and to sign informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPraluent (Alirocumab)
Alirocumab 300 mg injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07375225
Related Trials
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT0749117219 locations
An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia
NCT069742661 location
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
NCT0761027826 locations
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
NCT076149581 location
LATAM LOWERS LDL-C
NCT0650144311 locations